ARV-110, also known as bavdegalutamide, is an experimental PROTAC androgen receptor degrader in development for metastatic castration-resistant prostate cancer. It is designed to degrade androgen receptor protein rather than only inhibit receptor signaling. The asset remains investigational.
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03888612 |
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer |
COMPLETED | PHASE1/PHASE2 |
